Volume 10, supplement issue 4, December 2008

Controversies in Breast Cancer 2008

Issue editors

William R Miller
Mitch Dowsett
James N Ingle

26 articles in this issue

Controversies in Breast Cancer 2008

Authors
- William R Miller
- Content type: Preface
- Published: 18 December 2008
- Article: S1
Introduction to sessions on 'What can surgeons do for us (and we for them): radiology, pathology, molecular biology and local therapy'

Authors
- J Michael Dixon
- Monica Morrow
- Content type: Section introduction
- Published: 18 December 2008
- Article: S2
Thirty years of experience with mammography screening: a new approach to the diagnosis and treatment of breast cancer

Authors
- László Tabar
- Peter B Dean
- Content type: Short communication
- Published: 18 December 2008
- Article: S3
The utility of conventional and molecular pathology in managing breast cancer

Authors
- D Craig Allred
- Content type: Short communication
- Published: 18 December 2008
- Article: S4
How much can improved molecular and pathologic discriminants change local therapy?

Authors
- Monica Morrow
- Content type: Short communication
- Published: 18 December 2008
- Article: S5
Introduction to the sessions on 'Debate: Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors'

Authors
- Lesley Fallowfield
- David George
- Content type: Section introduction
- Published: 18 December 2008
- Article: S6
Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case for

Authors
- J Michael Dixon
- David A Montgomery
- Content type: Short communication
- Published: 18 December 2008
- Article: S7
Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case against

Authors
- David A Cameron
- Content type: Short communication
- Published: 18 December 2008
- Article: S8
Introduction to sessions on 'Predicting personal risk for breast cancer'

Authors
- Mitch Dowsett
- Content type: Section introduction
- Published: 18 December 2008
- Article: S9
Assessing individual risk for breast cancer: role of oestrogens and androgens

Authors
- Richard J Santen
- Content type: Short communication
- Published: 18 December 2008
- Article: S10
Should lifestyle modifications be promoted to prevent breast cancer?

Authors
- Anthony Howell
- Michelle Harvie
- Content type: Short communication
- Published: 18 December 2008
- Article: S11
Identification of personal risk of breast cancer: genetics

Authors
- Diana M Eccles
- Content type: Short communication
- Published: 18 December 2008
- Article: S12
Assessing risk for breast cancer

Authors
- Jack Cuzick
- Content type: Short communication
- Published: 18 December 2008
- Article: S13
Psychosocial aspects of risk appraisal

Authors
- Lesley Fallowfield
- Content type: Short communication
- Published: 18 December 2008
- Article: S14
Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to?'

Authors
- James N Ingle
- Content type: Section introduction
- Published: 18 December 2008
- Article: S15
By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy

Authors (first, second and last of 4)
- V Craig Jordan
- Roshani Patel
- Ramona F Swaby
- Content type: Short communication
- Published: 18 December 2008
- Article: S16
Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer

Authors
- James N Ingle
- Content type: Short communication
- Published: 18 December 2008
- Article: S17
Markers of endocrine sensitivity

Authors
- Daniel F Hayes
- Content type: Short communication
- Published: 18 December 2008
- Article: S18
Identification and mechanisms of endocrine resistance

Authors
- William R Miller
- Content type: Short communication
- Published: 18 December 2008
- Article: S19
Integration of endocrine therapy with targeted agents

Authors
- Stephen RD Johnston
- Content type: Short communication
- Published: 18 December 2008
- Article: S20
Introduction to sessions on 'Optimizing the implementation of future treatments – time to abandon traditional methods'

Authors
- Mark Verrill
- Content type: Section introduction
- Published: 18 December 2008
- Article: S21
Strength and weakness of phase I to IV trials, with an emphasis on translational aspects

Authors
- Per Eystein Lønning
- Content type: Short communication
- Published: 18 December 2008
- Article: S22
Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective?

Authors
- Kathleen I Pritchard
- Content type: Short communication
- Published: 18 December 2008
- Article: S23
Neoadjuvant/presurgical treatments

Authors
- Ian E Smith
- Content type: Short communication
- Published: 18 December 2008
- Article: S24
Evaluation of biological agents targeted at early-stage disease

Authors (first, second and last of 4)
- Marta Guix
- Ingrid A Mayer
- Carlos L Arteaga
- Content type: Short communication
- Published: 18 December 2008
- Article: S25
Optimizing the implementation of future treatment using surrogate end-points

Authors
- Mitch Dowsett
- Content type: Short communication
- Published: 18 December 2008
- Article: S26

Volume 10, supplement issue 4, December 2008

Controversies in Breast Cancer 2008

Controversies in Breast Cancer 2008

Introduction to sessions on 'What can surgeons do for us (and we for them): radiology, pathology, molecular biology and local therapy'

Thirty years of experience with mammography screening: a new approach to the diagnosis and treatment of breast cancer

The utility of conventional and molecular pathology in managing breast cancer

How much can improved molecular and pathologic discriminants change local therapy?

Introduction to the sessions on 'Debate: Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors'

Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case for

Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case against

Introduction to sessions on 'Predicting personal risk for breast cancer'

Assessing individual risk for breast cancer: role of oestrogens and androgens

Should lifestyle modifications be promoted to prevent breast cancer?

Identification of personal risk of breast cancer: genetics

Assessing risk for breast cancer

Psychosocial aspects of risk appraisal

Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to?'

By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy

Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer

Markers of endocrine sensitivity

Identification and mechanisms of endocrine resistance

Integration of endocrine therapy with targeted agents

Introduction to sessions on 'Optimizing the implementation of future treatments – time to abandon traditional methods'

Strength and weakness of phase I to IV trials, with an emphasis on translational aspects

Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective?

Neoadjuvant/presurgical treatments

Evaluation of biological agents targeted at early-stage disease

Optimizing the implementation of future treatment using surrogate end-points

For authors

Explore

Navigation

Volume 10, supplement issue 4, December 2008

Controversies in Breast Cancer 2008

Authors

Authors

Authors

Authors

Authors

Authors

Authors

Authors

Authors

Authors

Authors

Authors

Authors

Authors

Authors

Authors (first, second and last of 4)

Authors

Authors

Authors

Authors

Authors

Authors

Authors

Authors

Authors (first, second and last of 4)

Authors

For authors

Explore

Search

Navigation